|
|
Article: CryoCath completes enrollment in FROSTY pivotal IDE study for Freezor.(Freezor Trial of Supraventricular Tachycardia ()(Investigational Device Exemption )(Brief Article)
- Article from:
- Medical Devices & Surgical Technology Week
- Article date:
- May 26, 2002
CopyrightCOPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2002 MAY 26 - (NewsRx.com & NewsRx.net) -- CryoCath Technologies, Inc., announced it has successfully completed enrollment in its pivotal, 165 patient Freezor Trial of Supraventricular Tachycardia (FROSTY) Investigational Device Exemption (IDE) study.
"Completion of enrollment of the FROSTY study brings this unique technology one step closer to commercialization in the U.S.," said Peter L. Friedman, director of clinical cardiac electrophysiology laboratory, Cape Cod Hospital, Cape Cod, Massachusetts; staff electrophysiologist, Brigham & Women's Hospital, Boston, Massachusetts, and coprincipal investigator of the FROSTY study. "Throughout the course of this study ...